Clinical lung cancer

Keyphrases

Publications

volume 25, number 5, 2024

Hayley Nicole Roberts, Benjamin Solomon, Susan Harden, Senthil Lingaratnam, Marliese Alexander
Utility of 30-Day Mortality Following Systemic Anti-Cancer Treatment as a Quality Indicator in Advanced Lung Cancer. Clinical lung cancer 25 (5) (2024)
Parth Sharma, Himil Mahadevia, Sreekanth Donepudi, Lara Kujtan, Beth Gustafson, Ben Ponvilawan, Ammar Al-Obaidi, Janakiraman Subramanian, Dhruv Bansal
A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review. Clinical lung cancer 25 (5) (2024)
Yujin Kudo, Taiyo Nakamura, Jun Matsubayashi, Akimichi Ichinose, Yushi Goto, Ryosuke Amemiya, Jinho Park, Yoshihisa Shimada, Masatoshi Kakihana, Toshitaka Nagao, Tatsuo Ohira, Jun Masumoto, Norihiko Ikeda
AI-driven Characterization of Solid Pulmonary Nodules on CT Imaging for Enhanced Malignancy Prediction in Small-sized Lung Adenocarcinoma. Clinical lung cancer 25 (5) (2024)
Amit A Kulkarni, Cassandra Hennessy, Grace Wilson, Vidhyalakshmi Ramesh, Clara Hwang, Joy Awosika, Ziad Bakouny, Hina Khan, Diana Vilar-Compte, Rana McKay, Chinmay Jani, Lisa Weissmann, Elizabeth Griffiths, Gerald Batist, Nathaniel Bouganim, Blanche Mavromatis, Babar Bashir, Ryan H Nguyen, Jonathan W Riess, Matthew Puc, Anup Kasi, Stephanie Berg, Dan Ran Castillo, Brandon Hayes-Lattin, Wylie Hosmer, Daniel Flora, Sanjay Mishra, Benjamin French, Jeremy L Warner, Gilberto Lopes, Solange Peters, Narjust Florez
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis. Clinical lung cancer 25 (5) (2024)
Marcus Taylor, Matt Evison, Sarah Michael, Emmanuel Obale, Nils C Fritsch, Udo Abah, Matthew Smith, Glen P Martin, Michael Shackcloth, Felice Granato, Stuart W Grant, null null
Pre-Operative Measures of Systemic Inflammation Predict Survival After Surgery for Primary Lung Cancer. Clinical lung cancer 25 (5) (2024)
Lye-Yeng Wong, Sania Choudhary, Ntemena Kapula, Margaret Lin, Irmina A Elliott, Brandon A Guenthart, Douglas Z Liou, Leah M Backhus, Mark F Berry, Joseph B Shrager, Natalie S Lui
Barriers to Completing Low Dose Computed Tomography Scan for Lung Cancer Screening. Clinical lung cancer 25 (5) (2024)
Zhaojuan Jiang, Qingwan Li, Jinqiu Ruan, Yanli Li, Dafu Zhang, Yongzhou Xu, Yuting Liao, Xin Zhang, Depei Gao, Zhenhui Li
Machine Learning-Based Prediction of Pathological Responses and Prognosis After Neoadjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Retrospective Study. Clinical lung cancer 25 (5) (2024)
Matthew N Mills, Akihiro Uno, Pinxue Li, Casey Liveringhouse, Youngchul Kim, Daniel E Oliver, Bradford A Perez, Benjamin C Creelan, Michael Yu, Peter A Forsyth, Yolanda Pina, Kamran A Ahmed
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone. Clinical lung cancer 25 (5) (2024)
Hanbo Pan, Hang Chen, Weicheng Kong, Junwei Ning, Zhen Ge, Yu Tian, Ningyuan Zou, Hongda Zhu, Jiaqi Zhang, Yixing Tao, Zenan Gu, Min Zheng, Guomo Ruan, Long Jiang, Ziming Li, Jia Huang, Chengwei Zhou, Guodong Xu, Qingquan Luo
Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study. Clinical lung cancer 25 (5) (2024)
Iacopo Petrini, Rossella Bruno, Iosè Di Stefano, Vittorio Aprile, Stylianos Korasidis, Eleonora Pardini, Antonio Chella, Greta Alì
A patient with a Germline (p.R776H) EGFR Mutation With Multiple Lung Cancers Harboring Different Somatic EGFR Mutations. Clinical lung cancer 25 (5) (2024)
Amit A Kulkarni, Cassandra Hennessy, Grace Wilson, Vidhyalakshmi Ramesh, Clara Hwang, Joy Awosika, Ziad Bakouny, Hina Khan, Diana Vilar-Compte, Rana McKay, Chinmay Jani, Lisa Weissmann, Elizabeth Griffiths, Gerald Batist, Nathaniel Bouganim, Blanche Mavromatis, Babar Bashir, Ryan H Nguyen, Jonathan W Riess, Matthew Puc, Anup Kasi, Stephanie Berg, Dan Ran Castillo, Brandon Hayes-Lattin, Wylie Hosmer, Daniel Flora, Sanjay Mishra, Benjamin French, Jeremy L Warner, Gilberto Lopes, Solange Peters, Narjust Florez
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis. Clinical lung cancer 25 (5) (2024)
Andrew Fantoni, Lydia Warburton, Benjamin Solomon, Marliese Alexander, Meghana Maddula, Lauren Julia Brown, Ines Pires da Silva, Adnan Nagrial, Farah Abu Al-Hial, Malinda Itchins, Nick Pavlakis, Samantha Bowyer
Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT). Clinical lung cancer 25 (5) (2024)
Anne Gulbech Ording, Thomas Decker Christensen, Flemming Skjøth, Simon Noble, Anette Arbjerg Højen, Amalie Lambert Mørkved, Torben Bjerregaard Larsen, Rene Horsleben Petersen, Peter Meldgaard, Erik Jakobsen, Mette Søgaard
Risk of Venous Thromboembolism in Patients With Stage III and IV Non-Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study. Clinical lung cancer 25 (5) (2024)
Jessica Donington, Xiaohan Hu, Su Zhang, Yan Song, Ashwini Arunachalam, Diana Chirovsky, Chi Gao, Ari Lerner, Anya Jiang, James Signorovitch, Ayman Samkari
Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer. Clinical lung cancer 25 (5) (2024)
Yngvar Nilssen, Odd Terje Brustugun, Lars Fjellbirkeland, Bjørn Henning Grønberg, Per Magnus Haram, Nina Helbekkmo, Åslaug Helland, Sissel Gyrid Freim Wahl, Marianne Aanerud, Steinar Solberg
Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends. Clinical lung cancer 25 (5) (2024)

volume 25, number 6, 2024

Tomoyuki Hishida, Jiro Okami, Hisao Asamura, Etsuo Miyaoka, Yasushi Shintani, Mitsutaka Kadokura, Shunsuke Endo, Masayuki Chida, Hidemi Suzuki, Ichiro Yoshino, Hiroshi Date, null null
Clinicopathological Features and Survival Outcomes of Resected Lung Adenosquamous Carcinoma: Results From a Nationwide Japanese Registry Data. Clinical lung cancer 25 (6) (2024)
Vamsidhar Velcheti, Pragya Rai, Yu-Han Kao, Diana Chirovsky, Ana Tablante Nunes, Stephen V Liu
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC. Clinical lung cancer 25 (6) (2024)
Moritz Kleemiss, Christa E Müller, Marion Schneider, Rainer Strotmann, Katrin Orlowski, Kosalaram Goteti, Mert Yanik, Peter Brossart, Franz-Georg Bauernfeind
Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report. Clinical lung cancer 25 (6) (2024)
Chikako Iwai, Taisuke Jo, Takaaki Konishi, Asahi Fujita, Nobuaki Michihata, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched-Pair Cohort Study Using a Nationwide Inpatient Database. Clinical lung cancer 25 (6) (2024)
Martin Reck, Ernest Nadal, Nicolas Girard, Andrea R Filippi, Linda W Martin, Carl M Gay, Cordula Petersen, Davina Gale, Ugochinyere A Emeribe, Nefeli Georgoulia, Ignacio E Diaz Perez, Jonathan D Spicer
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC. Clinical lung cancer 25 (6) (2024)
Yuto Nonaka, Mitsuhiro Isaka, Keigo Matsushima, Shinya Katsumata, Hayato Konno, Tetsuya Mizuno, Toshiyuki Nagata, Akifumi Notsu, Kiyoshi Tone, Takuya Kawata, Masahiro Endo, Yasuhisa Ohde
Prediction of Pleural Lavage Cytology According to Thin-Section Computed Tomography in Non-Small-Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Paola Muscolino, Claudia Scimone, Elena Sapuppo, Vincenzo Micali, Ignazio Vasta, Anna Santacaterina, Mariacarmela Santarpia, Alessandro Russo
Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis? Clinical lung cancer 25 (6) (2024)
Xiancheng Wu, Laura P Stabile, Timothy F Burns
The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases. Clinical lung cancer 25 (6) (2024)
David R Gandara, Janakiraman Subramanian, Edgardo S Santos, Yehuda Brody, Itamar Sela, Yehonatan Elon, Michal Harel, Anat Reiner-Benaim, Coren Lahav, Kimberly McGregor
Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Muhammad Awidi, Angel Mier-Hicks, Stuthi Perimbeti, Kristopher Attwood, Hongbin Chen, Prantesh Jain, Edwin Yau, Amy Early, Grace K Dy
Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients? Clinical lung cancer 25 (6) (2024)
Muhammad Awidi, Angel Mier-Hicks, Stuthi Perimbeti, Kristopher Attwood, Hongbin Chen, Prantesh Jain, Edwin Yau, Amy Early, Grace K Dy
Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients? Clinical lung cancer 25 (6) (2024)
Moritz Kleemiss, Christa E Müller, Marion Schneider, Rainer Strotmann, Katrin Orlowski, Kosalaram Goteti, Mert Yanik, Peter Brossart, Franz-Georg Bauernfeind
Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report. Clinical lung cancer 25 (6) (2024)
Arpeet T Shah, Isabelle Blanchard, Sukhmani K Padda, Heather A Wakelee, Joel W Neal
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Hamza Rshaidat, Gregory L Whitehorn, Micaela Collins, Shale J Mack, Jonathan Martin, Tyler R Grenda, Nathaniel R Evans, Olugbenga T Okusanya
Factors Associated With Margin Positivity After Lung Resection Surgery. Clinical lung cancer 25 (6) (2024)
Lary A Robinson, Tawee Tanvetyanon, Noah A Robinson, Sandra Bryant, Alexis Bailey, Damon R Reed, Thomas Dilling
Surgery and Stereotactic Radiotherapy for Stage I Small-Cell Lung Carcinoma: A 25-Year Experience. Clinical lung cancer 25 (6) (2024)
Rachel L Minne, Natalie Y Luo, Anne M Traynor, Minxuan Huang, Luisina DeTullio, Jen Godden, Melissa Stoppler, Randall J Kimple, Andrew M Baschnagel
Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Arpeet T Shah, Isabelle Blanchard, Sukhmani K Padda, Heather A Wakelee, Joel W Neal
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Paola Muscolino, Claudia Scimone, Elena Sapuppo, Vincenzo Micali, Ignazio Vasta, Anna Santacaterina, Mariacarmela Santarpia, Alessandro Russo
Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis? Clinical lung cancer 25 (6) (2024)
Lary A Robinson, Tawee Tanvetyanon, Noah A Robinson, Sandra Bryant, Alexis Bailey, Damon R Reed, Thomas Dilling
Surgery and Stereotactic Radiotherapy for Stage I Small-Cell Lung Carcinoma: A 25-Year Experience. Clinical lung cancer 25 (6) (2024)
Daisuke Shibahara, Kentaro Tanaka, Osamu Togao, Yoshimasa Shiraishi, Yasuto Yoneshima, Eiji Iwama, Tadamasa Yoshitake, Kousei Ishigami, Isamu Okamoto
Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Rachel L Minne, Natalie Y Luo, Anne M Traynor, Minxuan Huang, Luisina DeTullio, Jen Godden, Melissa Stoppler, Randall J Kimple, Andrew M Baschnagel
Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Hamza Rshaidat, Gregory L Whitehorn, Micaela Collins, Shale J Mack, Jonathan Martin, Tyler R Grenda, Nathaniel R Evans, Olugbenga T Okusanya
Factors Associated With Margin Positivity After Lung Resection Surgery. Clinical lung cancer 25 (6) (2024)
Martin Reck, Ernest Nadal, Nicolas Girard, Andrea R Filippi, Linda W Martin, Carl M Gay, Cordula Petersen, Davina Gale, Ugochinyere A Emeribe, Nefeli Georgoulia, Ignacio E Diaz Perez, Jonathan D Spicer
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC. Clinical lung cancer 25 (6) (2024)
Xiancheng Wu, Laura P Stabile, Timothy F Burns
The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases. Clinical lung cancer 25 (6) (2024)
Vamsidhar Velcheti, Pragya Rai, Yu-Han Kao, Diana Chirovsky, Ana Tablante Nunes, Stephen V Liu
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC. Clinical lung cancer 25 (6) (2024)
Arpeet T Shah, Isabelle Blanchard, Sukhmani K Padda, Heather A Wakelee, Joel W Neal
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Yuto Nonaka, Mitsuhiro Isaka, Keigo Matsushima, Shinya Katsumata, Hayato Konno, Tetsuya Mizuno, Toshiyuki Nagata, Akifumi Notsu, Kiyoshi Tone, Takuya Kawata, Masahiro Endo, Yasuhisa Ohde
Prediction of Pleural Lavage Cytology According to Thin-Section Computed Tomography in Non-Small-Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Daisuke Shibahara, Kentaro Tanaka, Osamu Togao, Yoshimasa Shiraishi, Yasuto Yoneshima, Eiji Iwama, Tadamasa Yoshitake, Kousei Ishigami, Isamu Okamoto
Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Tomoyuki Hishida, Jiro Okami, Hisao Asamura, Etsuo Miyaoka, Yasushi Shintani, Mitsutaka Kadokura, Shunsuke Endo, Masayuki Chida, Hidemi Suzuki, Ichiro Yoshino, Hiroshi Date, null null
Clinicopathological Features and Survival Outcomes of Resected Lung Adenosquamous Carcinoma: Results From a Nationwide Japanese Registry Data. Clinical lung cancer 25 (6) (2024)
Chikako Iwai, Taisuke Jo, Takaaki Konishi, Asahi Fujita, Nobuaki Michihata, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched-Pair Cohort Study Using a Nationwide Inpatient Database. Clinical lung cancer 25 (6) (2024)
Arpeet T Shah, Isabelle Blanchard, Sukhmani K Padda, Heather A Wakelee, Joel W Neal
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
David R Gandara, Janakiraman Subramanian, Edgardo S Santos, Yehuda Brody, Itamar Sela, Yehonatan Elon, Michal Harel, Anat Reiner-Benaim, Coren Lahav, Kimberly McGregor
Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)
Samuel Keltner, Hope Esslinger, Xiaoyong Wu, Shesh Rai, Vinita Takiar
Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer. Clinical lung cancer 25 (6) (2024)
Samuel Keltner, Hope Esslinger, Xiaoyong Wu, Shesh Rai, Vinita Takiar
Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer. Clinical lung cancer 25 (6) (2024)
Arpeet T Shah, Isabelle Blanchard, Sukhmani K Padda, Heather A Wakelee, Joel W Neal
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical lung cancer 25 (6) (2024)